drugset / Trial / NCT04206943
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
Phase 1/2
Unknown
24 enrolled
Acibadem University
Acıbadem Atunizade Hospital · collabAcıbadem Labcell · collabThe Scientific and Technological Research Council of Turkey · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
It is a treatment that activates and strengthens the immune system against cancer. Recently, T cell receptors have been genetically rearranged by adaptive T cell therapies, which are promising in the fight against cancer, and are now able to recognize antigens on tumor cells. These modified T cell receptors are called chimeric antigen receptors. Many previous clinical studies have shown that different CAR-T cells are effective in relapse / refractory B cell cancers and NHL.
Timeline
- Start
- 2019-10-12
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | 4e+06 cells/kg | — |
| Subject | Axicabtagene Ciloleucel | Cell therapy | 6e+06 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | sodium chloride | Unknown | 2000 ml | Intravenous |